Bevaro 100 mg Injection is a prescription medication containing Bevacizumab, a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). It is used in the treatment of several types of cancers, including metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and cervical cancer.

By blocking VEGF, Bevaro prevents the growth of blood vessels that supply tumors, helping to starve cancer cells and slow disease progression. It is administered intravenously under medical supervision, often in combination with chemotherapy.